Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy
Open Access
- 13 February 2017
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (18) , 11158-11169
Abstract
Deferasirox (Def) is an iron-chelating drug used to reduce iron overload in β-thalassemia patients. After the discovery of its tumor growth inhibition, this drug gained tremendous attention in cancer chemotherapy. Herein, deferasirox and its derivatives including methoxy (mDef) and imidazole-modified (iDef) deferasirox were encapsulated in polymeric micelles. Results showed that the release of deferasirox from polymeric micelles was faster at pH 7.4 (physiological condition) than at pH 4.5 (lysosomal condition). However, the release of mDef was pH-independent where both Def and mDef are not suitable for in vivo applications. Therefore, iDef was synthesized to change the pKa from 3.7 (carbonyl group of Def) to 6.8 (imidazole group of iDef) without interfering the iron-chelating efficacy. Interestingly, the release rate of imidazole-modified deferasirox was conversed from that of deferasirox where it exhibited slow release at physiological condition and faster release at the lysosomal condition. This release profile showed a pH-response and an ON–OFF release behavior where iDef is encapsulated in micelles during systemic circulation and released inside cancer cells after intracellular endosomes/lysosome. Cytotoxicity of deferasirox and modified deferasirox were also investigated, and it was found that the IC50 against PC-3 and HepG2 cell lines were in the range of micromolar to submicromolar. Flow cytometry analysis confirmed a decrease in the amount of iron inside lysosome when cells were treated by iDef-loaded micelles. Therefore, iDef-loaded micelles have potential application in cancer treatment as a pH-responsive iron-chelating nanocarrier.Keywords
Funding Information
- Mahidol University
This publication has 45 references indexed in Scilit:
- Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?The Journal of Clinical Pharmacology, 2013
- A novel synergistic effect of iron depletion on antiangiogenic cancer therapyInternational Journal of Cancer, 2012
- Endocytosis at the nanoscaleChemical Society Reviews, 2012
- Nanoparticle PEGylation for Imaging and TherapyNanomedicine, 2011
- Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRGBioMetals, 2009
- Multifunctional Micellar Nanomedicine for Cancer TherapyExperimental Biology and Medicine, 2009
- Does the calcein-AM method assay the total cellular ‘labile iron pool’ or only a fraction of it?Biochemical Journal, 2007
- A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeuticsProceedings of the National Academy of Sciences, 2006
- Proton Diffusion across Membranes of Vesicles of Poly(styrene-b-acrylic Acid) Diblock CopolymersJournal of the American Chemical Society, 2006
- Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivoJournal of Hepatology, 2005